BI-1206 shine dan takarar jagoran magunguna na BioInvent kuma a halin yanzu ana bincike a cikin gwaji na Phase 1/2 guda biyu. Ɗaya yana kimanta haɗin BI-1206 tare da rituximab don maganin lymphoma na Non-Hodgkin, wanda ya haɗa da marasa lafiya tare da FL, MCL da lymphoma na yanki (MZL) waɗanda suka sake dawowa ko kuma suna da ra'ayin rituximab. Gwajin Mataki na biyu na 1/2 yana binciken BI-1206 a hade tare da maganin anti-PD1 Keytruda® (pembrolizumab) a cikin ciwace-ciwacen ciwace-ciwace.
Dr. Wei-Wu He, Shugaban CASI, kuma Shugaba yayi sharhi, "BioInvent yana ci gaba da samun ci gaba tare da ci gaba da tsarin tsarin BI-1206. Yarda da CTA a China a cikin Disamba 2021 da na kwanan nan na FDA Marayu Drug Design ya nuna ƙarfin ƙarfin wannan rigakafin-aji na farko. CASI tana da haƙƙin kasuwanci na China na BI-1026, kuma ƙungiyarmu tana shirye-shiryen nazarin asibiti na China. CASI da BioInvent abokan haɗin gwiwa ne marasa daidaituwa kuma suna da manufa ɗaya don amfanar marasa lafiya tare da sabbin fasahohin magunguna."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Ɗaya yana kimanta haɗin BI-1206 tare da rituximab don maganin lymphoma na Non-Hodgkin, wanda ya haɗa da marasa lafiya tare da FL, MCL da lymphoma na yanki (MZL) waɗanda suka sake dawowa ko kuma suna da ra'ayin rituximab.
- Yarda da CTA a China a watan Disamba 2021 da kuma kwanan nan na FDA Marayu na Magungunan Magunguna ya nuna ƙarfin ƙarfin wannan rigakafin-aji na farko.
- Gwajin Mataki na biyu na 1/2 yana binciken BI-1206 a hade tare da maganin anti-PD1 Keytruda® (pembrolizumab) a cikin ciwace-ciwacen ciwace-ciwace.
